The Effects of SCH 351125 [ancriviroc] on Mononuclear Cell Trafficking to Joints, Synovial Inflammation and Expression of Chemokines in Subjects With Rheumatoid Arthritis

Trial Profile

The Effects of SCH 351125 [ancriviroc] on Mononuclear Cell Trafficking to Joints, Synovial Inflammation and Expression of Chemokines in Subjects With Rheumatoid Arthritis

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Ancriviroc (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 14 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 17 Aug 2013 New source identified and integrated (ISRCTN: Current Controlled Trials: 87502236)
    • 24 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top